MET and cancer: Additionally, inhibition of Met using a MET inhibitor (PHA-665752) has been found to decrease the expression of glycolysis initiation-associated hexokinase 2 (HK2) and promote the reactivation of oxidative phosphorylation in cancer cells within a NSCLC model [134].